ArcticDx Inc. Unveils Pharmacogenetic Testing for Ocular Vitamin Therapy at ASRS
8/26/2013 7:52:02 AM
ArcticDx, Inc. announced that its Vita RiskTM pharmacogenetic analysis, which supports the genotype-directed selection of appropriate eye vitamin therapies for patients suffering from age-related macular degeneration (AMD), will be available as part of the new Macula Risk® PGx test launched at the ASRS meeting.
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by